Decellularized liver matrix as a carrier for the transplantation of human fetal and primary hepatocytes in mice

Ping Zhou, Nataly Lessa, Daniel C. Estrada, Ella B. Severson, Shilpa Lingala, Mark A Zern, Jan Nolta, Jian Wu

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

The transplantation of primary hepatocytes has been shown to augment the function of damaged livers and to bridge patients to liver transplantation. However, primary hepatocytes often have low levels of engraftment and survive for only a short time after transplantation. To explore the potential benefits of using decellularized liver matrix (DLM) as a carrier for hepatocyte transplantation, DLM from whole mouse livers was generated. Human fetal hepatocytes immortalized by telomerase reconstitution (FH-hTERTs) or primary human hepatocytes were infused into the DLM, which was then implanted into the omenta of immunodeficient nonobese diabetic/severe combined immunodeficient/ interleukin-2 receptor γ-deficient mice or nonobese diabetic/severe combined immunodeficient/mucopolysaccharidosis type VII mice. The removal of endogenous cellular components and the preservation of the extracellular matrix proteins and vasculature were demonstrated in the resulting DLM. Bioluminescent imaging revealed that FH-hTERTs transduced with a lentiviral vector expressing firefly luciferase survived in the DLM for 8 weeks after peritoneal implantation, whereas the luciferase signal from FH-hTERTs rapidly declined in control mice 3 to 4 weeks after transplantation via splenic injection or omental implantation after Matrigel encapsulation. Furthermore, primary human hepatocytes that were reconstituted in the DLM not only survived 6 weeks after transplantation but also maintained their function, as demonstrated by messenger RNA levels of albumin and cytochrome P450 (CYP) subtypes (CYP3A4, CYP2C9, and CYP1A1) similar to the levels in freshly isolated human primary hepatocytes (hPHs). In contrast, when hPHs were transplanted into mice via splenic injection, they failed to express CYP3A4, although they expressed albumin. In conclusion, DLM provides an excellent environment for long-term survival and maintenance of the hepatocyte phenotype after transplantation. Liver Transpl, 2011. © 2011 AASLD.

Original languageEnglish (US)
Pages (from-to)418-427
Number of pages10
JournalLiver Transplantation
Volume17
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Hepatocytes
Transplantation
Liver
Cytochrome P-450 CYP3A
Liver Transplantation
Albumins
Mucopolysaccharidosis VII
Firefly Luciferases
Inbred NOD Mouse
Cytochrome P-450 CYP1A1
Injections
Omentum
Interleukin-2 Receptors
Extracellular Matrix Proteins
Telomerase
Luciferases
Cytochrome P-450 Enzyme System
Maintenance
Phenotype
Messenger RNA

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Decellularized liver matrix as a carrier for the transplantation of human fetal and primary hepatocytes in mice. / Zhou, Ping; Lessa, Nataly; Estrada, Daniel C.; Severson, Ella B.; Lingala, Shilpa; Zern, Mark A; Nolta, Jan; Wu, Jian.

In: Liver Transplantation, Vol. 17, No. 4, 04.2011, p. 418-427.

Research output: Contribution to journalArticle

Zhou, Ping ; Lessa, Nataly ; Estrada, Daniel C. ; Severson, Ella B. ; Lingala, Shilpa ; Zern, Mark A ; Nolta, Jan ; Wu, Jian. / Decellularized liver matrix as a carrier for the transplantation of human fetal and primary hepatocytes in mice. In: Liver Transplantation. 2011 ; Vol. 17, No. 4. pp. 418-427.
@article{36481ca33b1a49f885d42bce9decad3e,
title = "Decellularized liver matrix as a carrier for the transplantation of human fetal and primary hepatocytes in mice",
abstract = "The transplantation of primary hepatocytes has been shown to augment the function of damaged livers and to bridge patients to liver transplantation. However, primary hepatocytes often have low levels of engraftment and survive for only a short time after transplantation. To explore the potential benefits of using decellularized liver matrix (DLM) as a carrier for hepatocyte transplantation, DLM from whole mouse livers was generated. Human fetal hepatocytes immortalized by telomerase reconstitution (FH-hTERTs) or primary human hepatocytes were infused into the DLM, which was then implanted into the omenta of immunodeficient nonobese diabetic/severe combined immunodeficient/ interleukin-2 receptor γ-deficient mice or nonobese diabetic/severe combined immunodeficient/mucopolysaccharidosis type VII mice. The removal of endogenous cellular components and the preservation of the extracellular matrix proteins and vasculature were demonstrated in the resulting DLM. Bioluminescent imaging revealed that FH-hTERTs transduced with a lentiviral vector expressing firefly luciferase survived in the DLM for 8 weeks after peritoneal implantation, whereas the luciferase signal from FH-hTERTs rapidly declined in control mice 3 to 4 weeks after transplantation via splenic injection or omental implantation after Matrigel encapsulation. Furthermore, primary human hepatocytes that were reconstituted in the DLM not only survived 6 weeks after transplantation but also maintained their function, as demonstrated by messenger RNA levels of albumin and cytochrome P450 (CYP) subtypes (CYP3A4, CYP2C9, and CYP1A1) similar to the levels in freshly isolated human primary hepatocytes (hPHs). In contrast, when hPHs were transplanted into mice via splenic injection, they failed to express CYP3A4, although they expressed albumin. In conclusion, DLM provides an excellent environment for long-term survival and maintenance of the hepatocyte phenotype after transplantation. Liver Transpl, 2011. {\circledC} 2011 AASLD.",
author = "Ping Zhou and Nataly Lessa and Estrada, {Daniel C.} and Severson, {Ella B.} and Shilpa Lingala and Zern, {Mark A} and Jan Nolta and Jian Wu",
year = "2011",
month = "4",
doi = "10.1002/lt.22270",
language = "English (US)",
volume = "17",
pages = "418--427",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Decellularized liver matrix as a carrier for the transplantation of human fetal and primary hepatocytes in mice

AU - Zhou, Ping

AU - Lessa, Nataly

AU - Estrada, Daniel C.

AU - Severson, Ella B.

AU - Lingala, Shilpa

AU - Zern, Mark A

AU - Nolta, Jan

AU - Wu, Jian

PY - 2011/4

Y1 - 2011/4

N2 - The transplantation of primary hepatocytes has been shown to augment the function of damaged livers and to bridge patients to liver transplantation. However, primary hepatocytes often have low levels of engraftment and survive for only a short time after transplantation. To explore the potential benefits of using decellularized liver matrix (DLM) as a carrier for hepatocyte transplantation, DLM from whole mouse livers was generated. Human fetal hepatocytes immortalized by telomerase reconstitution (FH-hTERTs) or primary human hepatocytes were infused into the DLM, which was then implanted into the omenta of immunodeficient nonobese diabetic/severe combined immunodeficient/ interleukin-2 receptor γ-deficient mice or nonobese diabetic/severe combined immunodeficient/mucopolysaccharidosis type VII mice. The removal of endogenous cellular components and the preservation of the extracellular matrix proteins and vasculature were demonstrated in the resulting DLM. Bioluminescent imaging revealed that FH-hTERTs transduced with a lentiviral vector expressing firefly luciferase survived in the DLM for 8 weeks after peritoneal implantation, whereas the luciferase signal from FH-hTERTs rapidly declined in control mice 3 to 4 weeks after transplantation via splenic injection or omental implantation after Matrigel encapsulation. Furthermore, primary human hepatocytes that were reconstituted in the DLM not only survived 6 weeks after transplantation but also maintained their function, as demonstrated by messenger RNA levels of albumin and cytochrome P450 (CYP) subtypes (CYP3A4, CYP2C9, and CYP1A1) similar to the levels in freshly isolated human primary hepatocytes (hPHs). In contrast, when hPHs were transplanted into mice via splenic injection, they failed to express CYP3A4, although they expressed albumin. In conclusion, DLM provides an excellent environment for long-term survival and maintenance of the hepatocyte phenotype after transplantation. Liver Transpl, 2011. © 2011 AASLD.

AB - The transplantation of primary hepatocytes has been shown to augment the function of damaged livers and to bridge patients to liver transplantation. However, primary hepatocytes often have low levels of engraftment and survive for only a short time after transplantation. To explore the potential benefits of using decellularized liver matrix (DLM) as a carrier for hepatocyte transplantation, DLM from whole mouse livers was generated. Human fetal hepatocytes immortalized by telomerase reconstitution (FH-hTERTs) or primary human hepatocytes were infused into the DLM, which was then implanted into the omenta of immunodeficient nonobese diabetic/severe combined immunodeficient/ interleukin-2 receptor γ-deficient mice or nonobese diabetic/severe combined immunodeficient/mucopolysaccharidosis type VII mice. The removal of endogenous cellular components and the preservation of the extracellular matrix proteins and vasculature were demonstrated in the resulting DLM. Bioluminescent imaging revealed that FH-hTERTs transduced with a lentiviral vector expressing firefly luciferase survived in the DLM for 8 weeks after peritoneal implantation, whereas the luciferase signal from FH-hTERTs rapidly declined in control mice 3 to 4 weeks after transplantation via splenic injection or omental implantation after Matrigel encapsulation. Furthermore, primary human hepatocytes that were reconstituted in the DLM not only survived 6 weeks after transplantation but also maintained their function, as demonstrated by messenger RNA levels of albumin and cytochrome P450 (CYP) subtypes (CYP3A4, CYP2C9, and CYP1A1) similar to the levels in freshly isolated human primary hepatocytes (hPHs). In contrast, when hPHs were transplanted into mice via splenic injection, they failed to express CYP3A4, although they expressed albumin. In conclusion, DLM provides an excellent environment for long-term survival and maintenance of the hepatocyte phenotype after transplantation. Liver Transpl, 2011. © 2011 AASLD.

UR - http://www.scopus.com/inward/record.url?scp=79953232380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953232380&partnerID=8YFLogxK

U2 - 10.1002/lt.22270

DO - 10.1002/lt.22270

M3 - Article

C2 - 21445925

AN - SCOPUS:79953232380

VL - 17

SP - 418

EP - 427

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 4

ER -